CD28 InhibitorPharmaceutical InformationUpdated on Mar 25, 2019 View more like this | Visit SHIRLEY, NY | Contact BOCSCI INC |
Inhibition of CD28
CD28 can be inhibited by some pharmacological drugs in multiple steps. In recent years, it has been proved on mouse model that CTLA4-Ig can be used as a blocker of CD28 signal, which can make mice tolerate alloantigen for a long time and become a potential immunosuppressant. CTLA4-Ig can make the host tolerate graft in experimental diabetic mice model, but has no obvious effect on humoral immunity, and can also make the completely mismatched rat heart and bone marrow grafts survive for a long time. In addition, CTLA4-IgM combined with immunosuppressant FK506 can reduce the dosage and side effects of the inhibitor.
CD28 and Diseases
CD28 plays an important role in autoimmune disease, tumor immunity, transplant rejection and aging. The regulation of CD28 involves the initiation, expansion, maintenance and down-regulation of the immune response. In addition, T cells may be involved in maturation, differentiation and down-regulation of autoreactive cell responses that have escaped thymus monitoring. At present, recombinant CTLA4-lg has been used to block CD28/B7 signal in order to inhibit humoral immunity, immune rejection, graft versus host disease, and alleviate autoimmune disease.
CD28 can be inhibited by some pharmacological drugs in multiple steps. In recent years, it has been proved on mouse model that CTLA4-Ig can be used as a blocker of CD28 signal, which can make mice tolerate alloantigen for a long time and become a potential immunosuppressant. CTLA4-Ig can make the host tolerate graft in experimental diabetic mice model, but has no obvious effect on humoral immunity, and can also make the completely mismatched rat heart and bone marrow grafts survive for a long time. In addition, CTLA4-IgM combined with immunosuppressant FK506 can reduce the dosage and side effects of the inhibitor.
CD28 and Diseases
CD28 plays an important role in autoimmune disease, tumor immunity, transplant rejection and aging. The regulation of CD28 involves the initiation, expansion, maintenance and down-regulation of the immune response. In addition, T cells may be involved in maturation, differentiation and down-regulation of autoreactive cell responses that have escaped thymus monitoring. At present, recombinant CTLA4-lg has been used to block CD28/B7 signal in order to inhibit humoral immunity, immune rejection, graft versus host disease, and alleviate autoimmune disease.
